
Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in technology and life sciences. Founded in December 2003, it has committed over $27 billion to more than 700 companies since inception.
Deal activity decreased year-over-year (2 deals in the last 12 months vs 7 prior). Average disclosed round size is $103.9M (across 73 rounds with reported amounts).
Portfolio
62
Fund Size
—
Top Stage
Growth
Last 12 Mo
2
Team
Mike Dutra
Senior Managing Director and Senior Investment Officer
Steve Kuo
Senior Managing Director and Group Head - Technology
Adam Soller
Managing Director
Brian Powers
Managing Director
Cristy Barnes
Managing Director
Ella Adhanan
Managing Director
Greg Peterson
Managing Director
James Downing
Managing Director
Jeffrey Ralto
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Series A | — | Oct 2026 | |
| HHawkeye | Series E | — | Mar 2026 |
| Series E | $150M | Dec 2025 | |
| Series D | $550M | Sep 2025 | |
| Series D | $550M | Sep 2025 | |
| Series F | $103M | Apr 2025 | |
| Growth | $200M | Jan 2025 | |
| Growth | — | Dec 2024 | |
| RRemodel Health | Unknown | $100M | Dec 2024 |
| SSynox Therapeutics | Pre-Seed | $92M | Oct 2024 |
| Growth | $125M | Oct 2024 | |
| Series A | $150M | May 2024 | |
| RRemodel Health | Unknown | $100M | Jan 2024 |
| SShiba Inu | Unknown | $12M | Jan 2024 |
| Growth | $200M | Jan 2024 | |
| Series F | $300M | Dec 2023 | |
| Series C | $166M | May 2023 | |
| Growth | $150M | May 2023 | |
| Series E | $230M | Feb 2023 | |
| Series C | $166M | Jan 2023 | |
| MMadrigal Pharmaceuticals | Unknown | $159M | Dec 2022 |
| Series F | $117M | Nov 2022 | |
| OOak Street Health | Unknown | $300M | Nov 2022 |
| Growth | $132M | Oct 2022 | |
| Debt | $100M | Apr 2022 |
Top Co-Investors
Last updated: 20 October 2026